Francesca Gatti

Summary

Country: Italy

Publications

  1. doi request reprint Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferon-alfa-2a
    Paola Nasta
    Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    AIDS 22:857-61. 2008
  2. doi request reprint Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis
    Francesca Gatti
    Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    J Antimicrob Chemother 63:575-8. 2009
  3. ncbi request reprint Treating hepatitis C virus in HIV patients: are side effects a real obstacle?
    Francesca Gatti
    Department of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    AIDS Rev 9:16-24. 2007
  4. doi request reprint HIV-related liver disease: ARV drugs, coinfection, and other risk factors
    Massimo Puoti
    Department of Infectious and Tropical Diseases, University of Brescia, AO Spedali Civili, Brescia, Italy
    J Int Assoc Physicians AIDS Care (Chic) 8:30-42. 2009
  5. ncbi request reprint Predictors of AIDS-defining events among advanced naïve patients after HAART
    Carlo Torti
    Institute for Infectious and Tropical Diseases, University of Brescia, Italy
    HIV Clin Trials 8:112-20. 2007
  6. ncbi request reprint Cellular HIV-1 DNA quantitation in patients during simplification therapy with protease inhibitor-sparing regimens
    Loredana Sarmati
    Department of Public Health and Cellular Biology, University of Rome Tor Vergata, Rome, Italy
    J Med Virol 79:880-6. 2007
  7. pmc Association between cellular human immunodeficiency virus DNA level and immunological parameters in patients with undetectable plasma viremia level during highly active antiretroviral therapy
    Loredana Sarmati
    Department of Public Health and Cellular Biology, University of Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
    J Clin Microbiol 43:6183-5. 2005
  8. ncbi request reprint Limited sampling strategy for the estimation of systemic exposure to the protease inhibitor nelfinavir
    Mario B Regazzi
    Department of Pharmacology, IRCCS Policlinico San Matteo, Pavia, Italy
    Ther Drug Monit 27:571-5. 2005
  9. pmc Clinical pharmacokinetics of nelfinavir and its metabolite M8 in human immunodeficiency virus (HIV)-positive and HIV-hepatitis C virus-coinfected subjects
    Mario Regazzi
    Clinical Pharmacokinetic Unit, Department of Pharmacology, IRCCS Policlinico San Matteo, Piazzale Golgi 1, 27100 Pavia, Italy
    Antimicrob Agents Chemother 49:643-9. 2005
  10. pmc High prevalence of M184 mutation among patients with viroimmunologic discordant responses to highly active antiretroviral therapy and outcomes after change of therapy guided by genotypic analysis
    Emanuele Nicastri
    Department of Public Health, University of Rome Tor Vergata, Rome, Italy
    J Clin Microbiol 41:3007-12. 2003

Collaborators

Detail Information

Publications10

  1. doi request reprint Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferon-alfa-2a
    Paola Nasta
    Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    AIDS 22:857-61. 2008
    ..To investigate the association between insulin resistance and rapid virologic response...
  2. doi request reprint Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis
    Francesca Gatti
    Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    J Antimicrob Chemother 63:575-8. 2009
    ..Liver stiffness at baseline and alanine aminotransferase levels at baseline and during follow-up were measured in order to find a correlation between drug levels and liver fibrosis or hepatotoxicity...
  3. ncbi request reprint Treating hepatitis C virus in HIV patients: are side effects a real obstacle?
    Francesca Gatti
    Department of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    AIDS Rev 9:16-24. 2007
    ....
  4. doi request reprint HIV-related liver disease: ARV drugs, coinfection, and other risk factors
    Massimo Puoti
    Department of Infectious and Tropical Diseases, University of Brescia, AO Spedali Civili, Brescia, Italy
    J Int Assoc Physicians AIDS Care (Chic) 8:30-42. 2009
    ..As more information about the mechanisms of drug related liver injury is known, clinicians will be better able to tailor therapies to suit individual situations, resulting in greater patient safety and outcomes...
  5. ncbi request reprint Predictors of AIDS-defining events among advanced naïve patients after HAART
    Carlo Torti
    Institute for Infectious and Tropical Diseases, University of Brescia, Italy
    HIV Clin Trials 8:112-20. 2007
    ..Baseline and follow-up predictors of new AIDS-defining events or death (ADE/death) among patients who started HAART late in their disease history have rarely been assessed simultaneously...
  6. ncbi request reprint Cellular HIV-1 DNA quantitation in patients during simplification therapy with protease inhibitor-sparing regimens
    Loredana Sarmati
    Department of Public Health and Cellular Biology, University of Rome Tor Vergata, Rome, Italy
    J Med Virol 79:880-6. 2007
    ..In addition, sustained suppression of the plasma viral load was significantly correlated with low levels of proviral DNA before treatment simplification...
  7. pmc Association between cellular human immunodeficiency virus DNA level and immunological parameters in patients with undetectable plasma viremia level during highly active antiretroviral therapy
    Loredana Sarmati
    Department of Public Health and Cellular Biology, University of Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
    J Clin Microbiol 43:6183-5. 2005
    ..005) CD4 counts and a prolonged duration of treatment (P = 0.001). At adjusted analysis, prolonged duration of treatment was independently associated with lower (P = 0.006) and undetectable (P < 0.001) HIV DNA values...
  8. ncbi request reprint Limited sampling strategy for the estimation of systemic exposure to the protease inhibitor nelfinavir
    Mario B Regazzi
    Department of Pharmacology, IRCCS Policlinico San Matteo, Pavia, Italy
    Ther Drug Monit 27:571-5. 2005
    ..The limited sampling strategy (LSS) described could be used in clinical practice for the easy assessment of the total exposure to NFV in HIV/HCV patients, both with and without cirrhosis...
  9. pmc Clinical pharmacokinetics of nelfinavir and its metabolite M8 in human immunodeficiency virus (HIV)-positive and HIV-hepatitis C virus-coinfected subjects
    Mario Regazzi
    Clinical Pharmacokinetic Unit, Department of Pharmacology, IRCCS Policlinico San Matteo, Piazzale Golgi 1, 27100 Pavia, Italy
    Antimicrob Agents Chemother 49:643-9. 2005
    ..Therefore, there may be a role for therapeutic drug monitoring in individualizing the NFV dosage in HIV-HCV-coinfected patients...
  10. pmc High prevalence of M184 mutation among patients with viroimmunologic discordant responses to highly active antiretroviral therapy and outcomes after change of therapy guided by genotypic analysis
    Emanuele Nicastri
    Department of Public Health, University of Rome Tor Vergata, Rome, Italy
    J Clin Microbiol 41:3007-12. 2003
    ..A relationship between the M184V mutation and a viroimmunologic discordant response to HAART was found. After the genotypic analysis-driven change of therapy, similar rates of virologic suppression were detected in the two groups...